Eurofins Discovery

Validation of HTP assays using human iPSC-derived cardiomyocytes to assess cardiotoxic compounds

Eurofins Discovery: The Essence of our Entrepreneurial Spirit

Eurofins Discovery: We Know What It Takes

Predicting Human Toxicities: A BioMAP® Platform Narrated Case Study

Leveraging the E3scanTM technology platform for next-generation targeted protein degradation

Comprehensive In Vitro Approach to Evaluating Transporter-mediated Drug Interactions

Find your Next Novel Kinase Inhibitor with the KINOMEscan Technology

Drug Discovery Trends & New Insights from Phenotypic Approaches

Implementing ADDC Assays in QC

Next-Generation Drug Discovery: Leveraging E3 Ligases for Targeted Protein Degradation

Eurofins Discovery Lowers Barriers to Innovation in Research & Development Through Collaboration

Critical Importance of Early Safety Screening in Drug Development

Accelerating hit finding programs: Echo MS and RapidFire-MS key advantages

Komabiotech Webinar - In Vivo Pharmacology and PK Services - Pharmacology Discovery Services (PDS)

Decoding Cancer and Inflammation: Identifying Selective Inhibitors of SH2 Domains

Identify & Characterize New, Potent & Selective Ligands with E3scan Ligand-Binding Assay Technology

An efficient and effective PIM3 kinase

Pharmacology Discovery Services - Capabilities Video

Versatile Hit-Finding Strategies for Successful Drug Discovery Programs

Successful Hit Finding for PIM3 Kinase Inhibitors: From HTS to Extended Hit Characterization

Eurofins Discovery IDD Highlights

Comprehensive Identification of Cardiovascular Safety Liabilities Using a Totality of Evidence

Eurofins Discovery: Virtual Screening

Biophysics in kinase drug discovery: FBS to PROTAC® ternary complex characterization

Eurofins Discovery Safety Pharmacology Portfolio